Bextra’s connection to side effects like Stevens-Johnson Syndrome continues to present a problem for hundreds of patients in the Atlanta area and thousands throughout the country who were prescribed and used the medication.
The FDA requested Pfizer to remove Bextra from the US market in April 2005. The request was made in light of the fact that the risks of Bextra usage to patients far outweighed the medications possible benefit.
Though the FDA stressed the risk of harmful cardiovascular events, which are commonly associated with non-steroidal anti-inflammatory drugs (NSAIDs), the FDA recognized that Bextra use showed a greater chance of experiencing serious skin reactions such as Steven-Johnson Syndrome.
Blisters, rashes, skin shedding, sore throat, swelling of the face and tongue is all symptoms of Stevens-Johnson syndrome. Unfortunately, these reactions aren’t predictable and can occur in patients who do not have a history of sulfa allergy, regardless of short-term or long-term usage.